Brent Saunders exits as Bausch + Lomb CEO by mutual agreement, replaced interim by Thomas Appio. Shares down 3%. Company to ...
Mirum's Livmarli, First Tracks' ANB033, and Tortugas' obuprazine showed positive Phase 3, 1b, and 2b trial results in liver ...
A trial testing admilparant in IPF succeeded at the lower 60 mg dose, while the higher 120 mg dose failed. And the GEP-NET ...
AstraZeneca says an imbalanced adult subgroup sank its Ph3 HICKORY trial of efzimfotase alfa in hypophosphatasia as the FDA ...
When it made its much-hyped Mythos available back on July 1, Anthropic said the AI model was so powerful it couldn’t allow the technology to be used for life sciences tasks. On Thursday, ...
Fresh from its rebrand last week, Novo CEO Maziar Mike Doustdar spelled out the strategic vision that goes along with it. At the Danish drugmaker’s capital markets day in London on Monday ...
PhRMA says FDA will get money it can spend only on hiring and keeping staff, to restore reviewer levels after the HHS layoffs ...
ARCH and Population Health launch Somnivera with a $10.5M-upfront deal for an ex-China sleep drug from Jiangsu Nhwa.
Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient ...
Welcome back to Endpoints Weekly! We unveiled our 2026 Women in Biopharma special project on Monday. Our team pored through nearly 200 nominations to reach this year’s list of 20 ...
Chan Zuckerberg Biohub launches $1.8B Virtual Biology Initiative with Meta, Google DeepMind, Isomorphic Labs, DOE, and NIH to ...
Roche partners with Hangzhou-based Defand Therapeutics in a ~$1B deal, under $10M upfront, to develop molecular glue ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results